Tags

Type your tag names separated by a space and hit enter

Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial.
J Card Fail. 2012 Aug; 18(8):600-6.JC

Abstract

BACKGROUND

Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) significantly improved outcomes in patients with advanced heart failure (HF) receiving background neurohormonal therapy in the African-American Heart Failure Trial (A-HeFT). In this analysis, we investigated treatment effects by age <65 or ≥65 years.

METHODS AND RESULTS

Time-to-event curves were produced by the Kaplan-Meier method. Hazard ratios were calculated with the Cox proportional hazards model. Baseline characteristics showed that patients ≥65 years old had less hypertensive and more ischemic HF, better quality of life (QoL) scores, higher plasma B-type natriuretic peptide and creatinine levels, and received less background neurohormonal therapy. Kaplan-Meier curves showed that FDC I/H improved mortality and event-free survival in elderly patients. The hazard ratios for mortality, first heart failure hospitalization, and event-free survival (both unadjusted and adjusted for baseline differences), were similar quantitatively and in direction of effect in both age groups.

CONCLUSIONS

In A-HeFT, FDC I/H improved outcomes in HF patients aged <65 or ≥65 years, despite significant baseline differences between these age groups. Patients aged ≥65 years, a group at greater mortality risk, had the greatest survival benefit from FDC I/H.

Authors+Show Affiliations

Department of Medicine, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York 10032, USA. ataylor@columbia.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22858074

Citation

Taylor, Anne L., et al. "Effect of Fixed-dose Combined Isosorbide Dinitrate/hydralazine in Elderly Patients in the African-American Heart Failure Trial." Journal of Cardiac Failure, vol. 18, no. 8, 2012, pp. 600-6.
Taylor AL, Sabolinski ML, Tam SW, et al. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. J Card Fail. 2012;18(8):600-6.
Taylor, A. L., Sabolinski, M. L., Tam, S. W., Ziesche, S., Ghali, J. K., Archambault, W. T., Worcel, M., & Cohn, J. N. (2012). Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. Journal of Cardiac Failure, 18(8), 600-6. https://doi.org/10.1016/j.cardfail.2012.06.526
Taylor AL, et al. Effect of Fixed-dose Combined Isosorbide Dinitrate/hydralazine in Elderly Patients in the African-American Heart Failure Trial. J Card Fail. 2012;18(8):600-6. PubMed PMID: 22858074.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. AU - Taylor,Anne L, AU - Sabolinski,Michael L, AU - Tam,S William, AU - Ziesche,Susan, AU - Ghali,Jalal K, AU - Archambault,W Tad, AU - Worcel,Manuel, AU - Cohn,Jay N, AU - ,, PY - 2010/03/22/received PY - 2012/06/08/revised PY - 2012/06/15/accepted PY - 2012/8/4/entrez PY - 2012/8/4/pubmed PY - 2012/12/18/medline SP - 600 EP - 6 JF - Journal of cardiac failure JO - J Card Fail VL - 18 IS - 8 N2 - BACKGROUND: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) significantly improved outcomes in patients with advanced heart failure (HF) receiving background neurohormonal therapy in the African-American Heart Failure Trial (A-HeFT). In this analysis, we investigated treatment effects by age <65 or ≥65 years. METHODS AND RESULTS: Time-to-event curves were produced by the Kaplan-Meier method. Hazard ratios were calculated with the Cox proportional hazards model. Baseline characteristics showed that patients ≥65 years old had less hypertensive and more ischemic HF, better quality of life (QoL) scores, higher plasma B-type natriuretic peptide and creatinine levels, and received less background neurohormonal therapy. Kaplan-Meier curves showed that FDC I/H improved mortality and event-free survival in elderly patients. The hazard ratios for mortality, first heart failure hospitalization, and event-free survival (both unadjusted and adjusted for baseline differences), were similar quantitatively and in direction of effect in both age groups. CONCLUSIONS: In A-HeFT, FDC I/H improved outcomes in HF patients aged <65 or ≥65 years, despite significant baseline differences between these age groups. Patients aged ≥65 years, a group at greater mortality risk, had the greatest survival benefit from FDC I/H. SN - 1532-8414 UR - https://www.unboundmedicine.com/medline/citation/22858074/Effect_of_fixed_dose_combined_isosorbide_dinitrate/hydralazine_in_elderly_patients_in_the_African_American_heart_failure_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1071-9164(12)00722-1 DB - PRIME DP - Unbound Medicine ER -